title: Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix.
abstract: In the iscom, antigen is attached by hydrophobic interactions to a matrix which is built up by the adjuvant Quil A and lipids. Thus, the iscom presents antigen in multiple copies on a small particle with a built-in adjuvant. By studying the specific antibody response, in vitro proliferation and IL-2 secretion by splenocytes from mice following different in vivo treatments with iscoms and/or matrix, we attempted to distinguish between nonspecific stimulatory effects, caused by the matrix or iscoms, and specific responses to the antigens incorporated into iscoms. The results strongly suggest that matrix and also iscoms exert a nonspecific adjuvant activity by a transient high spontaneous proliferation of cells collected within 2 weeks after administration of iscoms or matrix. This high rate of proliferation was preceded by suppressed proliferation, 3 days after injection with matrix or iscom. The adjuvant component included in iscoms, i.e., the matrix, does not excert a mitogenic stimulation in vitro or influence the levels of specific antibodies in serum. Specific responses to the antigens included in iscoms were recorded both as increasing levels of serum antibodies and as iscom-induced proliferation of immune spleen cells in vitro. The recruitment of IL-2 was only related to the specific stimulation induced by the antigens in iscom.
authors.affiliation: National Veterinary Institute, Department of Virology, Uppsala, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Fossum
authors.forename: M
authors.initials: M
authors.lastname: Bergström
authors.forename: K
authors.initials: K
authors.lastname: Lövgren
authors.forename: D L
authors.initials: DL
authors.lastname: Watson
authors.forename: B
authors.initials: B
authors.lastname: Morein
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000917:Antibody Formation; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D006389:Hemagglutinins, Viral / Q000276:immunology; D007114:Immunization; D007156:Immunologic Memory; D007376:Interleukin-2 / Q000097:blood*; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009439:Neuraminidase / Q000276:immunology; D062605:Quillaja Saponins; D012503:Saponins / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000941:Antigens; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D006389:Hemagglutinins, Viral; D007376:Interleukin-2; D062605:Quillaja Saponins; D012503:Saponins; D014764:Viral Proteins; C046386:Quil A; D009439:Neuraminidase